J Med Ethics. 2010 Sep;36(9):567-70. doi: 10.1136/jme.2010.036848. Epub 2010 Jul 26.
This paper argues that the National Institute for Health and Clinical Excellence should not offer guidance in situations where there is insufficient evidence equipoise about the potential benefit of the treatment in question. This is broadly for two reasons. First, without knowing if the treatment is effective no cost-effectiveness judgement can be logically made. Second, the implementation of a population wide change in treatment where there is equipoise amounts to a de facto clinical trial that falls outside the Clinical Trials Regulations. As such there are strong ethical and possibly legal grounds for preventing such an outcome. Guidance based upon insufficient evidence equipoise also impacts upon the clinical discretion possessed by individual medical professionals.
本文认为,在有关治疗效果的证据不足且没有定论的情况下,国家卫生与临床优化研究所不应提供指导。这主要有两个原因。首先,如果不知道治疗是否有效,就不可能进行合乎逻辑的成本效益判断。其次,在平衡状态下,对治疗方法进行广泛的人群改变相当于超出临床试验法规范围的事实上的临床试验。因此,有强有力的伦理和法律依据来防止这种结果。基于证据不足和平衡状态的指导也会影响到个别医疗专业人员的临床判断。